Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
Asset disposition
Cert. of designation
Director departure
Appointed director
ALIMERA SCIENCES INC (ALIM) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Appointed COO
Docs: "Deadline”). The Release Deadline will in no event be later than fifty days after Executive’s Separation. If Executive fails to return the executed Release on or before the Release Deadline, or if Executive revokes the Release within seven days after return of the executed Release, then Executive will not be entitled to the benefits described in this Section 5. Termination by Board without Cause or by Executive for Good Reason Not in Connection with Change in Control. If the Board terminates Executive’s employment without Cause or Executive resigns for Good Reason and a Separation occurs either more than three months prior to a Change in Control or more than 18 months after a Change in Control, the Company shall pay Executive his earned but unpaid base salary plus 100% of the sum of ...",
"Alimera Sciences Appoints Jason Werner as Chief Operating Officer"
08/23/2023 SC 13G Altium Capital Management LP reports a 5.7% stake in Alimera Sciences, Inc
08/16/2023 SC 13D/A Velan Capital Investment Management LP reports a 26% stake in Alimera Sciences, Inc.
08/15/2023 8-K Unregistered Sales of Equity Securities, Material Modifications to Rights of Security Holders, Changes in Control of Registra...
Docs: "CERTIFICATE OF ELIMINATION OF SERIES B CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC. Pursuant to Section 151 of the Delaware General Corporation Law"
08/14/2023 SC 13G LYTTON LAURENCE W reports a 5.7% stake in Alimera Sciences, Inc.
08/11/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 SC 13G Stonepine Capital Management, LLC reports a 10% stake in Alimera Sciences, Inc.
08/10/2023 SC 13G BOOTHBAY FUND MANAGEMENT, LLC reports a 9% stake in Alimera Sciences, Inc.
08/10/2023 8-K Quarterly results
Docs: "RECONCILIATION OF GAAP NET PRODUCT REVENUE TO NON-GAAP ADJUSTED NET PRODUCT REVENUE Three Months Ended Six Months Ended June 30, June 30, 2023 2022 2023 2022 GAAP NET PRODUCT REVENUE $ 17,538 $ 14,604 $ 31,084 $ 26,502 Adjustment to net product revenue: Foreign currency fluctuations, net 136 — — NON-GAAP ADJUSTED NET PRODUCT REVENUE $ 17,674 $ 14,604 $ 30,947 $"
08/03/2023 SC 13D/A Caligan Partners LP reports a 33.1% stake in Alimera Sciences, Inc.
08/03/2023 SC 13D/A Velan Capital Investment Management LP reports a 26% stake in Alimera Sciences, Inc.
08/02/2023 8-K Unregistered Sales of Equity Securities, Material Modifications to Rights of Security Holders, Departure of Directors or Cert...
Docs: "ALIMERA SCIENCES, INC. CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF DESIGNATION OF SERIES b CONVERTIBLE PREFERRED STOCK",
"Alimera Sciences, Inc. PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK",
"Appendix A Performance Criteria The Administrator may establish Performance Goals derived from one or more of the following criteria when it makes Awards of Restricted Shares or Restricted Stock Units that vest entirely or in part on the basis of performance or when it makes Performance Cash Awards: · Earnings · Sales or revenue · Earnings per share · Expense or cost reduction · Earnings before interest, taxes and depreciation · Working capital · Earnings before interest, taxes, depreciation and amortization · Economic value added · Total stockholder return · Market share · Return on equity or average stockholders’ equity · Cash measures including cash flow and cash balance · Return on assets, investment or capital employed &...",
"CHAIRMAN EMERITUS AGREEMENT"
08/01/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
07/13/2023 EFFECT Form EFFECT - Notice of Effectiveness:
07/12/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/30/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
06/29/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
06/29/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/09/2023 8-K Other Events  Interactive Data
05/31/2023 D/A Form D/A - Notice of Exempt Offering of Securities: [Amend]
05/19/2023 SC 13D/A Velan Capital Investment Management LP reports a 18.9% stake in Alimera Sciences, Inc.
05/18/2023 SC 13D/A Caligan Partners LP reports a 10% stake in Alimera Sciences, Inc.
05/18/2023 8-K Entered into consulting agreement, Appointed a new director
Docs: "Exhibit 2.1 PRODUCT RIGHTS AGREEMENT between EyePoint Pharmaceuticals, Inc. and Alimera Sciences, Inc. May 17, 2023",
"RESOLVED, that a new Section 7 is hereby added to the Certificate of Designation as follows: consummate a Liquidation Transaction. SECOND: The foregoing amendments were duly adopted in accordance with the provisions of Section 103 and 242 of the DGCL. IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed by its President and Chief Executive Officer on May 16, 2023. ALIMERA SCIENCES, INC.",
"In Witness Whereof, the Parties intending to be bound have caused this Commercial Supply Agreement to be executed by their duly authorized representatives as of the Effective Date. EYEPOINT PHARMACEUTICALS, INC. By: /s/ Nancy Lurker Name: Nancy Lurker Title: Chief Executive Officer ALIMERA SCIENCES, INC. By: /s/ Richard S. Eiswirth, Jr. Name: Richard S. Eiswirth, Jr. Title: Chief Executive Officer [Signature Page to Commercial Supply Agreement] EXHIBIT A PRODUCT SPECIFICATIONS [***] EXHIBIT B INITIAL ROLLING FORECAST [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***]",
"Exhibit 10.2",
"Alimera Acquires U.S. Commercial Rights to YUTIQ&#xAE"
05/15/2023 8-K Quarterly results
Docs: "Alimera Sciences Reports First Quarter 2023 Results"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
04/03/2023 SC 13G/A Palo Alto Investors LP reports a 0% stake in Alimera Sciences, Inc.
03/31/2023 10-K Annual Report for the period ended December 31, 2022
03/31/2023 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
03/28/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
03/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/27/2023 8-K Appointed a new director
Docs: "of the General Corporation Law of the State of Delaware)",
"CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC. Pursuant to Section 151 of the Delaware General Corporation Law",
"CERTIFICATE OF ELIMINATION OF SERIES C CONVERTIBLE PREFERRED STOCK, PAR VALUE $0.01 PER SHARE, OF ALIMERA SCIENCES, INC. Pursuant to Section 151 of the Delaware General Corporation Law",
"COMMON STOCK PURCHASE WARRANT ALIMERA SCIENCES, INC.",
"SCHEDULE B Tranche 2 Closing Purchaser Entities Shares of Series B Convertible Preferred Stock Aggregate Purchase Price Velan Capital Master Fund LP 7,500 $7,500,000 Caligan Partners LP, as investment manager for Boothbay Absolute Return Strategies LP 2,625 $2,625,000 Caligan Partners LP, as investment manager for Boothbay Diversified Alpha Fund Master Fund LP 1,750 $1,750,000 Caligan Partners LP, as investment manager for Caligan Partners Master Fund LP 3,125 $3,125,000 Total 15,000 $15,000",
"ARTICLE IV REGISTRATION EXPENSES 4.1 Registration Expenses. All reasonable fees and expenses incident to the performance of or compliance with this Agreement , except as and to the extent specified in this Section 4.1, shall be borne by the Company whether or not a Registration Statement is filed by the Company or becomes effective and whether or not any Registrable Securities are sold pursuant to a Registration Statement. In no event shall the Company be responsible for any underwriting, broker or similar fees or commissions of any Purchaser or, except to the extent provided for above or in the Transaction Documents, any legal fees or other costs of the Purchasers. The Company shall reimburse the Holders for the reasonable fees and disbursements of one legal counsel, which shall be Olshan...",
"Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy